Cohort Study of Adrenogenic Autonomic Cortisol Secretion

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-02-17

Study Completion Date

2033-02-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To investige the etiology, pathogenesis, diagnosis and treatment of adrenogenic autonomic cortisol secretion in Chinese adults.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Prevalence and Characteristics of Adrenal Incidentaloma

NCT04682938

Prevalence Adrenal Incidentaloma

COMPLETED

Optimizing Diagnosis Of Primary Aldosteronism

NCT02755519

Primary Aldosteronism

COMPLETED

Association Between Cortisol, Cortisone, Cotinine, Nicotine, Caffeine, Melatonin Levels in Hair, Serum, Urine, Saliva and Chronic Stress

NCT02403921

Hydrocortisone

UNKNOWN

The Construction of Precision Medicine in Chinese Medicine

NCT04434924

Hypertension

COMPLETED

D2 Dopamine Receptor on Human Aldosterone-Producing Adenoma and Its Role in Aldosterone Secretion and Cell Proliferation

NCT00173446

Hypertension Adrenal Aldosterone-Producing Adenoma

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

With the development of imaging detection technology and its wide application in clinic, the detection rate of adrenal incidentaloma (AI) has been greatly improved. In our previous study, 18.9% of AI were accompanied by autonomic cortisol secretion (ACS) in Chinese. The vast majority of ACS is mild (MACS). Due to the lack of typical Cushing manifestations and the low rate of progression to overt Cushing, MACS has received insufficient attention in the past. However, recent studies have found that MACS have a higher incidence of diabetes, hypertension, cardiovascular events, metabolic bone disease and mortality risk than those with non-functional adenomas. With appropriate treatment, the complications of MACS patients can be effectively improved. However, personalized treatment of MACS is a clinical difficulty. It is hard to determine whether the cortisol secretion of patients is caused by AI or whether patients will benifit from operation. There are some retrospective studies have provided some evidence, while prospective studies are lacking. The purpose of this study is to prospectively include patients with autonomic cortisol secretion, evaluate function and diagnosis, develop personalized treatment strategy, and follow up the prognosis. The research results will provide new evidence for standardized diagnosis and treatment of adrenogenic autonomic cortisol secretion in the future.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diagnosis Treatment Adrenogenic Autonomic Cortisol Secretion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study group

Accidental adrenal tumor with 1mg-DST cortisol \>50nmol/L

No interventions assigned to this group

Control group

Accidental adrenal tumor with 1mg-DST cortisol ≤50nmol/L

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* CT examination revealed adrenal nodules (maximum diameter ≥10mm);
* Serum cortisol \> 50nmol/L after 1mg dexamethasone inhibition test (1mg-DST).

Exclusion Criteria

* Patients with primary aldosteronism (PA), pheochromocytoma, adrenal metastatic carcinoma, congenital adrenal hyperplasia (CAH), ganglionic neuroma/paraganglioma, schwannoma, adrenal hematoma and those with no definite diagnosis were evaluated by clinical and endocrine function.
* Patients with serious underlying diseases (such as liver and kidney failure, acute severe infection, etc.) that may affect the function of the hypothalamic-pituitary-adrenal axis (HPA axis); Pregnancy.
* Patients with a history of alcoholism, fatigue, trauma, infection, depression, glucocorticoid use, and other drugs affecting the function of the hypothalamic-pituitary-adrenal axis.
* Patients who are not willing to participate in and complete this study refuse to sign the written informed consent for this study.

Eligible Sex

ALL

Accepts Healthy Volunteers

No